Is Telix Pharmaceuticals a buy after strong correction?
After a sharp correction in its share price Telix Pharmaceuticals has come back into investor focus. While recent regulatory setbacks have weighed heavily on sentiment, the company continues to deliver strong commercial execution and progress across its pipeline.
Telix Pharmaceuticals Limited (ASX: TLX)
has seen sharp correction in its share price despite delivering strong operational performance in FY25.
The disconnect between the fundamentals and market sentiment appears to be driven more by regulatory uncertainty than by deterioration in the underlying business.
The company achieved unaudited group revenue of $804m ($1.2bn) in FY25 in line with upgraded guidance with Q4 revenue up 46% YoY.
Growth was led by its Precision Medicine segment driven by sustained Illuccix sales and the successful U.S. launch of Gozellix following CMS reimbursement.
This highlights the scalability of the company’s commercial platform and validates its two product PSMA imaging strategy.
From a regulatory and pipeline perspective recent developments have been constructive.
The Chinese NMPA has accepted the New Drug Application for Illuccix supported by strong Phase 3 data showing a 94.8% positive predictive value and meaningful impact on treatment decisions.
China represents a large, underpenetrated prostate cancer imaging market and approval could materially expand the company’s addressable market over the medium term.
The company continues to advance a broad late-stage therapeutic pipeline. Multiple Phase 3 and pivotal studies are underway across prostate cancer, renal cell carcinoma and glioblastoma positioning the company for potential transition toward higher margin therapeutic revenues post 2027.
Management’s strategy of reinvesting commercial cash flows into therapeutics and manufacturing infrastructure appears intact supported by expanding global production capabilities.
Recent Complete Response Letters (CRLs) for Pixclara and Zircaix highlight ongoing regulatory execution risk while timelines for U.S. resubmissions and approvals remain uncertain. Near term share price performance is therefore likely to remain volatile and news flow driven.
The company’s current valuation appears to reflect elevated regulatory scepticism rather than weakening fundamentals. For investors with a higher risk tolerance and a medium to long term horizon the post correction levels may offer an attractive entry point.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
